Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseas...
Entia Biosciences reported revenue of $265,466 for fiscal year 2016, down 23.5% from fiscal year 2015, and net income of -$1.40 million.
Figures from company filings; latest fiscal year ended December 31, 2016.
No profile data available.